文献一覧: 高橋公太 (著者)

1 0 0 0 OA 書評ナイチンゲール「空気感染」対策の母

著者: 高橋公太
出版者: 一般社団法人日本臓器保存生物医学会
雑誌: Organ Biology (ISSN:13405152)
巻号頁・発行日: vol.30, no.2, pp.124-126, 2023 (Released:2023-09-01)
参考文献数: 2

2023-09-04 20:05:13
1 + 0 Twitter

1 0 0 0 OA 家族内発生 (兄弟) のミユラー管遺残症候群

著者: 新井啓川上芳明大澤哲雄波田野彰彦糸井俊之水澤隆樹筒井寿基谷川俊貴高橋公太
出版者: 一般社団法人日本泌尿器科学会
雑誌: 日本泌尿器科学会雑誌 (ISSN:00215287)
巻号頁・発行日: vol.94, no.4, pp.525-528, 2003-05-20 (Released:2010-07-23)
参考文献数: 19

症例は, 28歳男性および30歳男性の兄弟. 弟は左精巣の腫脹を主訴に受診し精巣腫瘍を疑われ手術となった. 術中, 子宮・卵管の遺残を認めたため, 交叉性精巣転移を伴うミュラー管遺残症候群に精巣腫瘍を合併したものと診断された. 兄は不妊症を主訴に受診し精巣の生検の際, 子宮・卵管の遺残を認め, 交叉性精巣転移を伴うミュラー管遺残症候群と診断された.

2023-08-30 16:23:47
1 + 0 Twitter

1 0 0 0 OA ABO血液型不適合腎移植なぜ超急性拒絶反応は発生しないのか

著者: 高橋公太
出版者: 一般社団法人日本臓器保存生物医学会
雑誌: Organ Biology (ISSN:13405152)
巻号頁・発行日: vol.18, no.1, pp.11-32, 2011-01-10 (Released:2013-11-26)
参考文献数: 27
被引用文献数: 1

It has now been over 20 years since we performed our first ABO-incompatible kidney transplantation(ABO-IKTx)in Japan. During that time about 1700 ABO-IKT have been performed. Since 2001 the success rate for these kidney transplants has been 96% for 1-year graft survival and 91% for 5-year graft survival, similar to results for ABO-compatible KTx. This dramatic improvement in results means that this transplantation procedure has become accepted for curative therapy in end-stage renal failure. Today ABO-IKTx accounts for 30% of all living KTx performed in Japan.In the 100 years since Karl Landsteiner discovered human ABO blood groups, the common wisdom has been that organ transplantation between incompatible blood groups would result immediately in hyperacute rejection and graft loss. However, this concept turned out to be a completely unsupported assumption. We provided epidemiological proof that hyperacute rejection was not caused by the ABO histo-blood group antigens(ABO HBGAS).We have reported elsewhere our two new ground-breaking findings regarding ABO-IKTx. We are confident that these findings will overturn the conventional wisdom about ABO-IKTx, and will mark a fundamental change in treatment strategies.The first finding involves ABO HBGAS, which are classed as carbohydrate antigens.Conventionally, emphasis has been placed on the saccharide chains only, and related phenomena have been interpreted accordingly. However, the saccharide chains in ABO histo-blood group antigens are present in the form of glycoproteins, and the binding proteins are termed " carrier proteins ". By employing proteomic analysis, we discovered that these binding proteins differ between the ABO HBGAS on the erythrocytic surface and those on the vascular endothelial cell surface. These new facts make it necessary to divide the ABO HBGAS into two broad categories.The antigens on the erythrocyte surface are ABO blood group antigens, while the antigens on the vascular endothelial cell surface are ABO histo group antigens.The lymphocytes probably do not identify the saccharides and binding proteins separately, but instead recognize them as part of a whole, and then proceed to form antibodies that have a high affinity for that whole. In other words, the recipient's anti-A/anti-B natural antibodies are primarily anti-ABO blood group antibodies, which do not have much affinity for the ABO histo group antigens on the vascular endothelial cell surface in the transplant organ. This is the main reason that hyperacute rejection is not induced by ABO incompatibility. The second finding relates to the known fact that ABO-incompatibility associated acute antibody-mediated rejection is caused by anti-A/anti-B antibodies. Conventionally it had been believed that this rejection response was caused by natural antibodies present in the recipient. However, if we consider the first theory, it becomes clear that the antibodies eliciting acute antibody-mediated rejection could not be produced without transplantation of the donor organ. That is to say, the recipient lymphocytes must be sensitized to the ABO histo group antigens on the vascular endothelial cells, resulting in the new production of anti-A/anti-B de novo antibodies. We have proven this fact indirectly elsewhere.After considering the new findings described above, we have established pretransplant desensitization therapy as the cornerstone of our transplantation treatment strategy.

2021-10-26 14:35:40
1 + 0 Twitter

1 0 0 0 血液透析中に起こる白血球数の一過性減少についての基礎的研究患者白血球の荷電変化による検討:―患者白血球の荷電変化による検討―

著者: 早坂勇太郎高橋公太東間紘阿岸鉄三杉野信薄太田和夫小路久敬打越由紀子峰島三千男江良和雄星野敏久高橋和雄寺岡慧
出版者: 一般社団法人日本人工臓器学会
雑誌: 人工臓器 (ISSN:03000818)
巻号頁・発行日: vol.17, no.1, pp.60-63, 1988

C/CA系のHD療法においてHD開始15-30分前後に補体活性化により患者白血球数が一過性に減少することが報告されてきた。一方、補体活性化作用のない抗OKT3モノクローナル抗体投与後も一過性の白血球減少を生じ、抗体結合後の荷電の変化によることも推察された。このため陽(陰)イオン交換樹脂を用いて白血球に対する吸着率を検討した結果、HD患者白血球では陰イオン交換樹脂に対する吸着率が高いだけではなく、正常白血球ではみられなかった陽イオン交換樹脂にたいしても80%以上の吸着率を示した。またHD患者白血球はHD開始15分前後に陰イオン交換樹脂に対する吸着率が低下し、この時期の患者血漿を正常白血球に添加、incubateすると正常白血球の陰イオン交換樹脂に対する吸着率が増加した。

2021-09-11 08:15:06
1 + 0 Twitter

1 0 0 0 OA 腎移植患者に対する薬剤師業務免疫抑制薬の感受性試験と服薬指導

著者: 杉山健太郎磯貝和也坂爪重明外山聡佐藤博齋藤和英中川由紀田﨑正行高橋公太平野俊彦
出版者: 一般社団法人日本臓器保存生物医学会
雑誌: Organ Biology (ISSN:13405152)
巻号頁・発行日: vol.18, no.1, pp.47-51, 2011-06-10 (Released:2014-11-26)
参考文献数: 10

Renal transplant recipients are administered immunosuppressive therapy to prevent acute rejection. In particular, new immunosuppressive agents have helped to improve the allograft survival rate and reduce the rate of rejection in renal transplant recipients. The optimal dose of calcineurin inhibitors is determined by therapeutic drug monitoring. However, the pharmacological efficacy of cyclosporine and tacrolimus should be estimated using both pharmacokinetics and pharmacodynamic parameters. We therefore employed the lymphocyte immunosuppressant sensitivity test(LIST) with the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide(MTT)assay procedure to evaluate renal transplant recipients. The LIST with the MTT assay procedure can predict the pharmacological efficacy of immunosuppressive drugs using peripheral blood mononuclear cellsMoreover, renal transplant recipients must be correctly treated with immunosuppressive agents and another medicines. Therefore, the pharmacist must provide instructions for all medications to maintain adherence in renal transplantation. Therefore, transplantation therapy must be based on the pharmaceutical care given by pharmacists.